<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00913497</url>
  </required_header>
  <id_info>
    <org_study_id>2009-089</org_study_id>
    <nct_id>NCT00913497</nct_id>
  </id_info>
  <brief_title>The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children</brief_title>
  <official_title>Phase 4 Crossover Study Comparing the Effect of Insulin Glulisine to Insulin Aspart on Breakfast Post Prandial Blood Glucose Levels in Prepubertal Children With Type 1 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Health Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helen DeVos Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spectrum Health Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether insulin glulisine decreases the breakfast post prandial glycemic
      excursion in comparison to insulin aspart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a treatment, open label, crossover study comparing two and four hour breakfast post
      prandial blood glucose levels after receiving a dose of insulin glulisine or insulin aspart
      administered subcutaneously and consuming the breakfast meal from a prescribed menu
      containing 45, 60 or 75 grams of carbohydrate. Each subject will receive insulin glulisine
      for ten days and insulin aspart for ten days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the two hour and four hour post prandial blood glucose levels following administration of insulin glulisine versus insulin aspart at the end of the twenty study days</measure>
    <time_frame>45 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of symptomatic hypoglycemia; hyperglycemia with ketonuria; systemic allergic reactions; localized injection site reactions</measure>
    <time_frame>45 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>insulin glulisine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin aspart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glulisine</intervention_name>
    <description>Insulin glulisine (Apidra速) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days</description>
    <arm_group_label>insulin glulisine</arm_group_label>
    <other_name>(Apidra速)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart</intervention_name>
    <description>Insulin aspart (NovoLog速) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.</description>
    <arm_group_label>insulin aspart</arm_group_label>
    <other_name>(NovoLog速)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  current patient in the Helen DeVos Children's Hospital Diabetes Clinic;

          -  ages 4-11 years;

          -  prepubertal (Tanner Stage I);

          -  diagnosed with type 1 diabetes mellitus with positive islet cell antibodies or
             presenting at time of diagnosis with positive serum or urine ketones and requiring
             insulin since diagnosis;

          -  at least six months from date of diagnosis of type 1 diabetes mellitus;

          -  TSH within reference range and negative transglutaminase IgA antibodies within nine
             months of study start;

          -  HbA1C between 6.9 and 10% within 30 days of study start; parent or guardian able and
             willing to provide written informed consent prior to enrollment;

          -  at time of study start, current insulin regimen includes multiple daily injections
             with insulin glargine as the basal insulin and insulin aspart or insulin lispro as the
             pre-meal rapid acting insulin

        Exclusion Criteria:

          -  pubertal (Tanner stage 2 or greater);

          -  concurrent Addison's disease, celiac disease or untreated hypothyroidism; - receiving
             oral, injectable or inhaled steroids or immunosuppressant medications;

          -  receiving stimulants for treatment of attention deficit disorder or attention deficit
             hyperactivity disorder;

          -  intercurrent illnesses such as a fever &gt; 101 degrees F, infection, or gastroenteritis;

          -  use of any medication to treat diabetes other than those listed under in inclusion
             criteria;

          -  potential for lack of compliance or any other issue which, in the opinion of the
             investigator, would compromise the subject's safety or successful participation in the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayse P Cemeroglu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helen DeVos Childrens Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helen DeVos Childrens Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>April 3, 2014</last_update_submitted>
  <last_update_submitted_qc>April 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spectrum Health Hospitals</investigator_affiliation>
    <investigator_full_name>Ayse Cemeroglu</investigator_full_name>
    <investigator_title>Physician, Endocrine Diabetes</investigator_title>
  </responsible_party>
  <keyword>Type 1 diabetes mellitus in children</keyword>
  <keyword>insulin glulisine</keyword>
  <keyword>insulin aspart</keyword>
  <keyword>post prandial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

